tradingkey.logo
tradingkey.logo
Buscar

Trinity Biotech PLC

TRIB
Añadir a la lista de seguimiento
0.377USD
+0.020+5.49%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
7.25MCap. mercado
PérdidaP/E TTM

Más Datos de Trinity Biotech PLC Compañía

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Información de Trinity Biotech PLC

Símbolo de cotizaciónTRIB
Nombre de la empresaTrinity Biotech PLC
Fecha de salida a bolsaOct 21, 1992
Director ejecutivoGillard (John)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 21
DirecciónIda Business Park, Bray, Co Wicklow
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal18
Teléfono01135312955111
Sitio Webhttps://www.trinitybiotech.com/
Símbolo de cotizaciónTRIB
Fecha de salida a bolsaOct 21, 1992
Director ejecutivoGillard (John)

Ejecutivos de Trinity Biotech PLC

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Trinity Biotech PLC?

Los cinco principales accionistas de Trinity Biotech PLC son: Mr. Ronan O'caoimh

¿Cuántas instituciones poseen acciones de Trinity Biotech PLC (TRIB)?

A fecha de 2026Q1, 50 instituciones poseen acciones de Trinity Biotech PLC, con un valor de mercado combinado de aproximadamente 876.37K, lo que representa el 4.33% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2074917.00.

¿Cuál es la mayor fuente de ganancias de Trinity Biotech PLC?

El 2026Q1, el segmento empresarial Clinical Laboratory generó la ganancia más alta para Trinity Biotech PLC, ascendiendo a 42.29M y representando el 74.41% de la ganancia total.